AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01367444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR422459
Description: Pharmaceutical form: sterile solution, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection
Study NCT04378374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: Baked food made of lentil flour
Study NCT04378374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Baked food made of lentil flour and wheat flour
Study NCT04378374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-3
Description: Baked food made of wheat flour
Study NCT04378374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-4
Description: Potable water (energy and carbohydrate-free control)
Study NCT03754790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitusiran
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT01372007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120mg
Description: Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
Study NCT01372007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are \<10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
Study NCT01314599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
Description: PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183.
Study NCT01163474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate video clinic visit prior to Face-to-Face usual care visit
Description: Evaluate video clinic visit prior to Face-to-Face usual care visit
Study NCT00943046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker therapy
Description: Implantation of the SIELLO pacemaker leads
Study NCT00827554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
Study NCT00827554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
Study NCT00827554 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
Study NCT00827554 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
Study NCT04374786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calm Meditation App
Description: Meditation is a self-management strategy that can be utilized by anyone to assist with the management of stress. Meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time.
Study NCT02493842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transverse Intrafasicular Multichannel electrode (TIME)
Description: Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
Study NCT04228198 — intervention group
Intervention type: PROCEDURE
Intervention: Radical cystectomy
Description: Procedure/Surgery: Radical cystectomy. Removal of urinary bladder with three different approaches: i) Robotic-assisted, ii) Laparoscopic, and iii) Open Surgery
Study NCT00003477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT04088929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
Study NCT00358982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 administered orally three times per wek
Study NCT03201237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: Each child observed a task video and then performed a task
Study NCT03201237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Action observation training
Description: Each child observed a task video and then performed a task
Study NCT01191554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: High and low dosage. Loading dose followed by continuous infusion in operation.
Study NCT04107597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Description: Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
Study NCT04107597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization exercises and paced breathing training
Description: Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
Study NCT04107597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point release
Description: A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
Study NCT04107597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point release and paced breathing training
Description: A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
Study NCT04449237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
Study NCT04449237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
Study NCT04449237 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: music therapy
Description: music therapy: therapeutic sound according to the frequency and loudness of each patient's tinnitus sound, so as to reduce the tinnitus sound.
Study NCT04869150 — intervention group
Intervention type: PROCEDURE
Intervention: radial access coronary angiography
Description: The right radial artery was cannulated with a 6-f radial sheath after local infiltration with 2% lidocaine.All patients received 5000 units of unfractionated heparin, 100 - 200 μg (depending on blood pressure) of nitroglycerin and 5 mg of diltiazem unless there was an absolute contraindication to diltiazem and anticoagulants.Coronary angiography was performed using the standard Judkins' technique via right radial access with a 5-f diagnostic catheter
Study NCT03747887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Report Card
Description: Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
Study NCT00312052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg and/or 100 mg placebo tablets
Study NCT01160380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
Study NCT01160380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: armodafinil
Description: Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
Study NCT01160380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
Study NCT03182491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)
Description: Analysis of biomarkers and basophil activation test
Study NCT02084433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraosseous anaesthesia using a computerized system
Description: 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection
Study NCT02084433 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anasthesia
Description: para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
Study NCT02356107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan and Creatine monohydrate
Study NCT04723836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy
Study NCT04723836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin (5mg)
Description: From 16th week gestation until end of pregnancy
Study NCT04723836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (400µg)
Description: From 16th week gestation until end of pregnancy
Study NCT04723836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From 16th week gestation until end of pregnancy
Study NCT02249689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definitive 65
Study NCT03747887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School as Usual
Description: The Individualized Education Program will be implemented as usual, with no additional study-related supports.
Study NCT02249689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Definitive 74
Study NCT04102332 — intervention group
Intervention type: DEVICE
Intervention: Safe Infusion Device
Description: Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
Study NCT02552953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Study NCT03882957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained attention
Description: participants will complete a sustained attention task
Study NCT03882957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: media multi-task
Description: participants will complete multiple media tasks at the same time
Study NCT03882957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: participants will watch a video of media tasks being completed
Study NCT03046056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily
Study NCT03046056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT03046056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily
Study NCT02247271 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diabetes health coach support
Description: Receives support from a trained peer health coach for a six month period
Study NCT00692458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: odanacatib
Description: odanacatib; 5mg oral, once daily for approximately 60 months.
Study NCT02215746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 powder for oral solution
Study NCT02215746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 tablet
Study NCT02215746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study NCT04624607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transspinal-transcortical paired-associative stimiulation combined with robotic gait training
Description: Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive transspinal stimulation and non-invasive brain stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study NCT04624607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcortical-transspinal paired-associative stimiulation combined with robotic gait training
Description: Individuals with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also paired non-invasive brain stimulation and non-invasive transspinal stimulation during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study NCT01211132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cap - Transparent retractable extension device.
Description: Attaching a Cap - Transparent retractable extension device.
Study NCT01211132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Without attaching a transparent cap to the tip of colonoscope.
Study NCT02927496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients \<50 kg)
Study NCT02927496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
Study NCT01903759 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study NCT00585325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instilled 1% Lidocaine
Description: 5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
Study NCT00585325 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% Normal Saline)
Description: .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
Study NCT00460356 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00460356 — intervention group
Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Undergo lymphadenectomy
Study NCT03319810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: FDA approved human normal immunoglobulin solution ready for intravenous administration
Study NCT00692458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo; oral, once daily for approximately 60 months
Study NCT02366403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SKY meditation
Description: SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
Study NCT02366403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPT-C
Description: CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
Study NCT00882661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SECURE-C Cervical Artificial Disc
Description: Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
Study NCT00882661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASSURE Cervical plate and an allograft interbody spacer
Description: Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
Study NCT01379105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neural mobilization
Description: In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
Study NCT01379105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Static Stretching
Description: In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
Study NCT03004547 — intervention group
Intervention type: OTHER
Intervention: Measuring sodium content
Description: Sodium MRI measurement of sodium content in the tissues of all participants
Study NCT01171469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells
Description: 5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
Study NCT01171469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
Study NCT02614690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Split Cast of forearm fractures
Description: Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months.